Stricter regulations, pricing control slow down pharma sector growth

Rajesh Desai (name changed on request) is pensive. Only four months into his new job in the quality assurance department at pharma company Ratnamani Healthcare, Desai has seen the staff level fall from 12 to below 10. What worries him is that there are no plans to replace his two colleagues. Working at the company’s unit at one of the largest clusters in Changodar in Ahmedabad, Desai blames the slowdown. He can see it in the declining batches of parenteral (drugs intended to be administered via infusion or injection) arriving for quality checks. As against 5-6 batches of the .....

Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.